Revenue up 15.6% as Optune Pax launches; operating loss narrows 73% on margin gains

Filed July 23, 2026 · Period ending June 30, 2026 · Compared to 10-Q Jul 24, 2025 · ~2 min read

Key Changes

• high

  Operating loss narrowed 73% YoY to $10.6M in Q2 2026 (from $39.5M in Q2 2025) as revenue grew 15.6% to $183.6M and gross margin expanded 400 bp to 78%, driven by 18% active-patient growth, a $4.9M tariff refund, and lower array costs.

  MD&A: Operating Results verify on EDGAR →
• high

  Optune Pax launched in the U.S. following FDA approval in February 2026, with 285 active patients as of June 30, 2026, and 418 prescriptions received in Q2 2026. The product also received CE certification in Europe and regulatory approval in Japan.

  MD&A: Product Launches verify on EDGAR →
• high

  Phase 3 TRIDENT trial in newly diagnosed GBM failed to meet its primary endpoint of overall survival improvement (17.7 months Early Start vs. 17.5 months Maintenance Start, HR 0.953, p=0.519), a setback for the GBM development program.

  MD&A: Clinical Trials verify on EDGAR →